Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $50,084.16 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Well Van sold 6,168 shares of SOPHiA GENETICS stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $8.12, for a total value of $50,084.16. Following the completion of the sale, the insider owned 332,716 shares in the company, valued at approximately $2,701,653.92. This trade represents a 1.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Well Daan Van also recently made the following trade(s):

• On Friday, September 11th, Well Van sold 6,168 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.63, for a total value of $47,061.84.

SOPHiA GENETICS Price Performance

SOPHiA GENETICS stock opened at $7.41 on Friday. SOPHiA GENETICS SA has a one year low of $3.75 and a one year high of $8.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The business has a fifty day moving average of $7.91 and a two-hundred day moving average of $6.16. The company has a market cap of $621.62 million, a P/E ratio of -6.44 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. The company had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. As a group, analysts predict that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on SOPH. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. HC Wainwright upped their price target on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, BTIG Research raised their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Hedge Funds Weigh In On SOPHiA GENETICS

Several hedge funds have recently bought and sold shares of SOPH. First Dallas Securities Inc. acquired a new position in shares of SOPHiA GENETICS in the first quarter worth $50,000. Royal Bank of Canada lifted its position in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after acquiring an additional 18,781 shares in the last quarter. AXQ Capital LP acquired a new stake in shares of SOPHiA GENETICS during the second quarter valued at $119,000. Silverberg Bernstein Capital Management LLC boosted its stake in shares of SOPHiA GENETICS by 8.7% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after acquiring an additional 4,155 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. purchased a new stake in SOPHiA GENETICS during the 2nd quarter worth about $567,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.